• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Telaglenastat addition to cabozantinib did not demonstrate benefit in pre-treated advanced renal cell carcinoma

byJohan PushaniandSze Wah Samuel Chan
September 12, 2022
in Chronic Disease, Nephrology, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Telaglenastat addition to cabozantinib did not show improvements in clinical benefit.

2. Adverse events of grades 3 or 4 occurred slightly less in the combination arm, with the most common consisting of hypertension and diarrhea.

Evidence Rating Level: 1 (Excellent)

Study Rundown: In preclinical trials, telaglenastat (an oral glutaminase inhibitor) showed synergy with cabozantinib (an inhibitor of multiple tyrosine kinase receptors) in renal cell carcinoma (RCC). This study explored the efficacy and safety of telaglenastat and cabozantinib in patients with advanced RCC who had disease progression on first and second-line therapies, specifically at least one antiangiogenic therapy or nivolumab plus ipilimumab. Patients were randomly assigned to receive cabozantinib and either telaglenastat or placebo. Median progression-free survival (PFS), both investigator-assessed and independent radiology committee-adjudicated (IRC), were not statistically significant between the two arms. Overall response rates (ORR) and median duration of response were marginally higher in the combination arm. Occurrence of treatment-emergent adverse events (TEAEs) were similar between arms. TEAEs of grades 3 or 4 occurred slightly less in the combination arm, with the most common events being hypertension and diarrhea. More patients discontinued treatment due to adverse events from cabozantinib in the placebo group than the combination group. Limitations to this study include a predominantly male population and the absence of biomarkers that could provide knowledge on the effects of each agent on glucose and glutamine metabolism. The strength of this study is that is has limited bias given its design. Also, while telaglenastat did not show benefit with cabozantinib, it did not exacerbate adverse events associated with cabozantinib, potentially making it worthwhile to test telaglenastat with other therapeutic partners. Overall, telaglenastat is not a viable therapeutic partner for cabozantinib.

Click to read the study in JAMA Oncology

Relevant Reading: Combination drug regimens for metastatic clear cell renal cell carcinoma

In-Depth [randomized control trial]: This international phase II trial included 444 patients with metastatic clear-cell RCC following progression on first and second-line therapies, including at least one antiangiogenic therapy or nivolumab plus ipilimumab. Patients were randomly assigned in a 1:1 ratio to receive either telaglenastat plus cabozantinib or placebo plus cabozantinib; 221 were in the former arm and 223 were in the latter arm. Median IRC-assessed PFS was 9.2 months and 9.3 months in the combination group and placebo group, respectively (hazard ratio [HR], 0.94; 95% confidence interval [CI], 0.74 to 1.21; P=0.65). Median investigator-assessed PFS was 9.2 months and 8.4 months, respectively (HR, 1.00; 95% CI, 0.79 to 1.25; P=0.97). ORR was 31% and 28%, respectively. Median duration of response was 12.0 months and 11.2 months, respectively. TEAEs of grades 3 and 4 occurred in 71% of patients in the combination group and in 79% in the placebo group, with the most common events being hypertension (17% in combination group vs. 18% in placebo group) and diarrhea (15% vs. 13%, respectively). Adverse events that led to the discontinuing of cabozantinib occurred in 10% of patients in the combination group and 15% of patients in the placebo group. Overall, telaglenastat did not improve the efficacy of cabozantinib in metastatic RCC.

RELATED REPORTS

Nivolumab plus ipilimumab does not improve survival in post-nephrectomy patients with renal cell carcinoma

Atezolizumab does not reduce post-resection recurrence in patients with renal cell carcinoma

Lenvatinib plus pembrolizumab show similar health-related quality-of-life outcomes in patients with advanced renal cell carcinoma compared to sunitinib

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: advanced renal cell carcinomacabozantinibtelaglenastat
Previous Post

Repeated low-level red light therapy significantly slows progression of myopia in children

Next Post

Functional testing nonsuperior to routine care for percutaneous coronary intervention patients

RelatedReports

Tenofovir disoprovil fumarate HIV prophylaxis linked with minimal kidney impact
Chronic Disease

Nivolumab plus ipilimumab does not improve survival in post-nephrectomy patients with renal cell carcinoma

March 21, 2023
Tenofovir disoprovil fumarate HIV prophylaxis linked with minimal kidney impact
Chronic Disease

Atezolizumab does not reduce post-resection recurrence in patients with renal cell carcinoma

October 11, 2022
Increased number of daily steps linked with decreased mortality in older women

Lenvatinib plus pembrolizumab show similar health-related quality-of-life outcomes in patients with advanced renal cell carcinoma compared to sunitinib

May 2, 2022
Oncology

Cabozantinib may be a viable first-line treatment in metastatic renal cell collecting duct carcinoma

April 25, 2022
Next Post
Shorter time to angioplasty may improve heart attack outcomes

Functional testing nonsuperior to routine care for percutaneous coronary intervention patients

Sleep duration inversely related to childhood type 2 diabetes risk makers

COVID-19 associated with higher gestational weight gain

Parent/child feeding practices associated with weight status

Commercial weight loss programs lead to greater weight loss than do-it-yourself methods

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Transcarotid artery revascularization not associated with a significant difference in 30-day risk of stroke, death and myocardial infarction compared to carotid endarterectomy
  • Drinking characteristics in adolescence predict alcohol behaviors in early adulthood
  • Sodium-glucose co-transporter-2 inhibitors may decrease risk of in-stent thrombosis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options